National Health Commission of the People’s Republic of China, Department of Mental Health (2020) Diagnostic and treatment guidelines for mental disorders. People’s Medical Publishing House, Beijing

Google Scholar 

Rehm J, Shield KD (2019) Global burden of disease and the impact of mental and addictive disorders. Curr Psychiatry Rep 21(2):10 Published 2019 Feb 7. https://doi.org/10.1007/s11920-019-0997-0

Article  PubMed  Google Scholar 

GBD2017DandIIandPC (2018) Global, regional, and National incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017 [published correction appears in lancet. 2019;393(10190):e44. Doi: 10.1016/S0140-6736(19)31047-5]. Lancet 392(10159):1789–1858. https://doi.org/10.1016/S0140-6736(18)32279-7

Whiteford HA, Ferrari AJ, Vos T (2016) Challenges to estimating the true global burden of mental disorders. Lancet Psychiatry 3(5):402–403. https://doi.org/10.1016/S2215-0366(16)30026-8

Article  PubMed  Google Scholar 

Vigo D, Thornicroft G, Atun R (2016) Estimating the true global burden of mental illness. Lancet Psychiatry 3(2):171–178. https://doi.org/10.1016/S2215-0366(15)00505-2

Article  PubMed  Google Scholar 

Dodd S, Bauer M, Carvalho AF et al (2021) A clinical approach to treatment resistance in depressed patients: what to do when the usual treatments don’t work well enough? World J Biol Psychiatry 22(7):483–494. https://doi.org/10.1080/15622975.2020.1851052

Article  PubMed  Google Scholar 

Siskind D, Orr S, Sinha S et al (2022) Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. Br J Psychiatry 220(3):115–120. https://doi.org/10.1192/bjp.2021.61

Article  PubMed  Google Scholar 

Gribkoff VK, Kaczmarek LK (2017) The need for new approaches in CNS drug discovery: why drugs have failed, and what can be done to improve outcomes. Neuropharmacology 120:11–19. https://doi.org/10.1016/j.neuropharm.2016.03.021

Article  CAS  PubMed  Google Scholar 

Firth J, Siddiqi N, Koyanagi A et al (2019) The lancet psychiatry commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry 6(8):675–712. https://doi.org/10.1016/S2215-0366(19)30132-4

Article  PubMed  Google Scholar 

Morgan VA, Waterreus A, Jablensky A et al (2012) People living with psychotic illness in 2010: the second Australian National survey of psychosis. Aust N Z J Psychiatry 46(8):735–752. https://doi.org/10.1177/0004867412449877

Article  PubMed  Google Scholar 

Vancampfort D, Correll CU, Galling B et al (2016) Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry 15(2):166–174. https://doi.org/10.1002/wps.20309

Article  PubMed  PubMed Central  Google Scholar 

Boccardi V, Murasecco I, Mecocci P (2019) Diabetes drugs in the fight against alzheimer’s disease. Ageing Res Rev 54:100936. https://doi.org/10.1016/j.arr.2019.100936

Article  CAS  PubMed  Google Scholar 

Gantois I, Popic J, Khoutorsky A, Sonenberg N (2019) Metformin for treatment of fragile X syndrome and other neurological disorders. Annu Rev Med 70:167–181. https://doi.org/10.1146/annurev-med-081117-041238

Article  CAS  PubMed  Google Scholar 

Blonde L, Dipp S, Cadena D. Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations [published correction appears in Adv Ther. 2018 Jul;35(7):966. doi: 10.1007/s12325-018-0729-6]. Adv Ther. 2018;35(7):939–965. https://doi.org/10.1007/s12325-018-0694-0

Bailey CJ (2017) Metformin: historical overview. Diabetologia 60(9):1566–1576. https://doi.org/10.1007/s00125-017-4318-z

Article  CAS  PubMed  Google Scholar 

Lv Z, Guo Y (2020) Metformin and its benefits for various diseases. Front Endocrinol (Lausanne) 11:191 Published 2020 Apr 16. https://doi.org/10.3389/fendo.2020.00191

Article  PubMed  Google Scholar 

O’Connor L, Bailey-Whyte M, Bhattacharya M et al (2024) Association of Metformin use and cancer incidence: a systematic review and meta-analysis. J Natl Cancer Inst 116(4):518–529. https://doi.org/10.1093/jnci/djae021

Article  PubMed  PubMed Central  Google Scholar 

Galal MA, Al-Rimawi M, Hajeer A, Dahman H, Alouch S, Aljada A (2024) Metformin: A Dual-Role player in Cancer treatment and prevention. Int J Mol Sci 25(7):4083 Published 2024 Apr 6. https://doi.org/10.3390/ijms25074083

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sillars B, Davis WA, Hirsch IB, Davis TM (2010) Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle diabetes study. Diabetes Obes Metab 12(9):757–765. https://doi.org/10.1111/j.1463-1326.2010.01230.x

Article  CAS  PubMed  Google Scholar 

Lamanna C, Monami M, Marchionni N, Mannucci E (2011) Effect of Metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 13(3):221–228. https://doi.org/10.1111/j.1463-1326.2010.01349.x

Article  CAS  PubMed  Google Scholar 

Sacco M, Ribaldone DG, Saracco GM (2023) Metformin and hepatocellular carcinoma risk reduction in diabetic patients with chronic hepatitis C: fact or fiction?? Viruses 15(12):2451 Published 2023 Dec 17. https://doi.org/10.3390/v15122451

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bhat A, Sebastiani G, Bhat M (2015) Systematic review: preventive and therapeutic applications of Metformin in liver disease. World J Hepatol 7(12):1652–1659. https://doi.org/10.4254/wjh.v7.i12.1652

Article  PubMed  PubMed Central  Google Scholar 

Neven E, Vervaet B, Brand K et al (2018) Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder. Kidney Int 94(1):102–113. https://doi.org/10.1016/j.kint.2018.01.027

Article  CAS  PubMed  Google Scholar 

Ekperikpe US, Mandal S, Holt SJ et al (2023) Metformin reduces insulin resistance and attenuates progressive renal injury in prepubertal obese Dahl salt-sensitive rats. Am J Physiol Ren Physiol 325(3):F363–F376. https://doi.org/10.1152/ajprenal.00078.2023

Article  CAS  Google Scholar 

Patrone C, Eriksson O, Lindholm D (2014) Diabetes drugs and neurological disorders: new views and therapeutic possibilities. Lancet Diabetes Endocrinol 2(3):256–262. https://doi.org/10.1016/S2213-8587(13)70125-6

Article  CAS  PubMed  Google Scholar 

Li N, Zhou T, Fei E (2022) Actions of Metformin in the brain: A new perspective of Metformin treatments in related neurological disorders. Int J Mol Sci 23(15):8281 Published 2022 Jul 27. https://doi.org/10.3390/ijms23158281

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dodd S, Sominsky L, Siskind D et al (2022) The role of Metformin as a treatment for neuropsychiatric illness. Eur Neuropsychopharmacol 64:32–43. https://doi.org/10.1016/j.euroneuro.2022.09.002

Article  CAS  PubMed  Google Scholar 

Correll CU, Sikich L, Reeves G et al (2020) Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial. World Psychiatry 19(1):69–80. https://doi.org/10.1002/wps.20714

Article  PubMed  PubMed Central  Google Scholar 

Kessing LV, Rytgaard HC, Ekstrøm CT, Knop FK, Berk M, Gerds TA (2020) Antidiabetes agents and incident depression: A nationwide Population-Based study. Diabetes Care 43(12):3050–3060. https://doi.org/10.2337/dc20-1561

Article  CAS  PubMed  Google Scholar 

Zhou JB, Tang X, Han M, Yang J, Simó R (2020) Impact of antidiabetic agents on dementia risk: A bayesian network meta-analysis. Metabolism 109:154265. https://doi.org/10.1016/j.metabol.2020.154265

Article  CAS  PubMed  Google Scholar 

Kuan YC, Huang KW, Lin CL, Hu CJ, Kao CH (2017) Effects of Metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus. Prog Neuropsychopharmacol Biol Psychiatry 79(Pt B):77–83. https://doi.org/10.1016/j.pnpbp.2017.06.002